Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Neurology
Advertisement
Lundbeck Reports Positive Phase IIb Migraine Trial Data
VALBY, Denmark, June 4, 2026 H. Lundbeck A/S has announced encouraging results from its Phase IIb PROCEED clinical trial...
Lundbeck and Cradle Harness AI to Accelerate CNS Drug Discovery
VALBY, Denmark and AMSTERDAM, Netherlands, June 3, 2026 Lundbeck and Cradle have announced a strategic partnership aimed at transforming...
Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
Advertisements
Amgen’s IMDYLLTRA Wins EU Approval for Small Cell Lung Cancer
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
NeuroPace Wins FDA Approval for AI-Powered Epilepsy Tool
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
Ono Pharma Highlights New Phase 2 MSA Data
OSAKA, Japan — May 28, 2026 Ono Pharmaceutical Co., Ltd. announced the presentation of new clinical data from its...
Emalex Ecopipam Phase 3 Tourette Data Published
CHICAGO, Ill., May 26, 2026 Emalex Biosciences announced that Phase 3 clinical data for ecopipam, its investigational dopamine-1 (D1)...
Advertisement
